Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
TYRA Tyra Biosciences Inc
- Stocks
- Healthcare
- NASDAQ: TYRA
Price (delayed)
$9.1
Market cap
$483.92M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.63
Enterprise value
$388.32M
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective
Highlights
The debt has declined by 6% year-on-year
The EPS has declined by 8% since the previous quarter but it is up by 3% year-on-year
Tyra Biosciences's quick ratio has decreased by 49% YoY and by 4.3% from the previous quarter
TYRA's net income is down by 28% YoY and by 12% QoQ
Key stats
What are the main financial stats of TYRA
Market
Valuations
Earnings
Shares outstanding
53.18M
Market cap
$483.92M
Enterprise value
$388.32M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.49
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$113.73M
Net income
-$96.44M
EBIT
-$96.44M
EBITDA
-$95.9M
Free cash flow
-$73.75M
Per share
Balance sheet
Liquidity
EPS
-$1.63
EPS diluted
-$1.63
Free cash flow per share
-$1.24
Book value per share
$6.09
Revenue per share
$0
TBVPS
$5.79
Total assets
$343.48M
Total liabilities
$19.94M
Debt
$6.12M
Equity
$323.53M
Working capital
$310.32M
Debt to equity
0.02
Current ratio
22.78
Quick ratio
22.46
Net debt/EBITDA
1
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-26.1%
Return on equity
-27.5%
Return on invested capital
-36.6%
Return on capital employed
-29.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TYRA stock price
How has the Tyra Biosciences stock price performed over time
Intraday
-7.43%
1 week
-1.41%
1 month
3.17%
1 year
-41.1%
YTD
-34.53%
QTD
-2.15%
Financial performance
How have Tyra Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$113.73M
Net income
-$96.44M
Gross margin
N/A
Net margin
N/A
The operating income has contracted by 29% YoY and by 9% from the previous quarter
TYRA's net income is down by 28% YoY and by 12% QoQ
Price vs fundamentals
How does TYRA's price correlate with its fundamentals
Growth
What is Tyra Biosciences's growth rate over time
Valuation
What is Tyra Biosciences stock price valuation
P/E
N/A
P/B
1.49
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has declined by 8% since the previous quarter but it is up by 3% year-on-year
The P/B is 35% below the last 4 quarters average of 2.3
Tyra Biosciences's equity has decreased by 17% YoY and by 6% QoQ
Efficiency
How efficient is Tyra Biosciences business performance
The return on invested capital has surged by 59% year-on-year but it has declined by 2.2% since the previous quarter
The ROA has contracted by 17% from the previous quarter but it has grown by 3.3% YoY
The ROE has contracted by 17% from the previous quarter but it has grown by 3.8% YoY
Dividends
What is TYRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TYRA.
Financial health
How did Tyra Biosciences financials performed over time
Tyra Biosciences's quick ratio has decreased by 49% YoY and by 4.3% from the previous quarter
The company's current ratio fell by 49% YoY and by 4.3% QoQ
The debt is 98% smaller than the equity
Tyra Biosciences's equity has decreased by 17% YoY and by 6% QoQ
The debt has declined by 6% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.